Hans-Peter Bøhn is a Norwegian citizen with a medical degree. He started his pharmaceutical industry career as medical adviser in Nycomed Imaging. Over the ensuing 12 years he gained broad experience from management positions in the pharmaceutical industry within drug safety, international marketing and operations and clinical research as well as gaining a post-graduate Diploma of Pharmaceutical Medicine. After the years in the industry he joined Fondsfinans as a financial analyst covering the life science sector. From 2012 he has been manager of the non-profit “Svanhild og Arne Musts Fond for Medisinsk Forskning” as well as serving as an independent adviser to among others the Research Council of Norway, the Norwegian Cancer Society, Innovation Norway, Oslo Cancer Cluster as well as a number of biotech start-up companies. Hans-Peter serves as a Board member of PCI Biotech, SpinChip Diagnostics and Cura8 and joined the board of Zelluna in September 2018.